×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

ID: MRFR/Pharma/36951-HCR
100 Pages
Rahul Gotadki
October 2025

Marktforschungsbericht zu Nicht-Peptid-Medikamenten von Angiotensin-II-Rezeptor-Antagonisten nach Verabreichungsweg (oral, intravenös, subkutan), nach Therapiegebiet (Bluthochdruck, Herzinsuffizienz, chronische Nierenerkrankung), nach Vertriebskanal (Krankenhausapotheken, Einzelhandelsapotheken, Online-Apotheken), nach Formulierungstyp (Tabletten, Injektionen, flüssige Formulierungen) und nach Regionen (Nordamerika, Europa, Südamerika, Asien-Pazifik, Naher Osten und Afrika) – Prognose bis 2034

Teilen
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
 Infographic
Purchase Options

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Zusammenfassung

Zu den wichtigsten Unternehmen im Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market -Markt gehören

Berichtsumfang

Einen Kommentar hinterlassen

FAQs

What is the projected market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2035?

The projected market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2035 is 6.52 USD Billion.

What was the market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2024?

The market valuation for Non-Peptide Drugs of Angiotensin II Receptor Antagonists in 2024 was 4.275 USD Billion.

What is the expected CAGR for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market from 2025 to 2035?

The expected CAGR for the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market during the forecast period 2025 - 2035 is 3.91%.

Which therapeutic area is projected to have the highest market value in 2035?

Chronic Kidney Disease is projected to have the highest market value in 2035, with an expected valuation of 2.4 USD Billion.

What are the leading companies in the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market?

Key players in the market include Novartis, Boehringer Ingelheim, AstraZeneca, Sanofi, Pfizer, Eli Lilly, Merck & Co., and Teva Pharmaceutical Industries.

How does the market for oral formulations compare to intravenous formulations in 2035?

In 2035, the market for oral formulations is expected to reach 3.8 USD Billion, while intravenous formulations are projected to reach 1.5 USD Billion.

What distribution channel is anticipated to generate the highest revenue by 2035?

Hospital Pharmacies are anticipated to generate the highest revenue by 2035, with a projected valuation of 2.3 USD Billion.

What is the expected market value for liquid formulations in 2035?

The expected market value for liquid formulations in 2035 is 1.12 USD Billion.

How does the market for heart failure treatments compare to hypertension treatments in 2035?

In 2035, the market for heart failure treatments is projected to reach 1.8 USD Billion, compared to 2.3 USD Billion for hypertension treatments.

What is the projected market value for online pharmacies in 2035?

The projected market value for online pharmacies in 2035 is 2.12 USD Billion.

Kostenloses Muster herunterladen

Bitte füllen Sie das folgende Formular aus, um ein kostenloses Muster dieses Berichts zu erhalten

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions